Hemorrhoid Drugs Market Analysis

The global hemorrhoid drugs market is segmented by end-user into hospitals, home care, specialty clinics, and others, out of which, the hospitals segment is anticipated to hold the largest share over the forecast period owing to the complications associated with the disease. The homecare segment is also estimated to witness significant growth by the end of 2036, owing to the increasing acceptance of homecare for the older patients. On the basis of disease type, the external hemorrhoids segment is anticipated to garner major market share over the forecast period, owing to the use of drugs as a treatment approach for external hemorrhoids, whereas, surgery is preferred for internal hemorrhoids.

Our in-depth analysis of the global market includes the following segments

By Drug Type	Topical Steroid Topical Anesthetics Others
By Disease Type	Internal Hemorrhoids External Hemorrhoids
By Distribution Channel	Offline Online
By End User	Hospitals Home Care Specialty Clinics Others

Frequently Asked Questions (FAQ)

Growing prevalence of piles or hemorrhoids on the back of poor diet, lifestyle diseases and obesity, is the major factor driving the market growth.

The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2021-2029.

Social shame and stigma related to hemorrhoids is a major factor estimated to hamper the market growth.

The market in Europe will provide the highest growth opportunities for the market during the forecast period on the back of increasing geriatric population and improving healthcare sector.

The major players in the market are Taro Pharmaceutical Industries Ltd., AstraZeneca, The Himalaya Drug Company, Panacea Biotec Ltd., Abbott Healthcare Private Limited, Sanofi-aventis Groupe, Pfizer Inc., Purdue Pharma L.P and others.

Hemorrhoid Drugs Market Analysis